Humacyte adds Scott Coward and Paul Kuznik to board ahead of planned ATEV dialysis launch

Humacyte, Inc.

Board appointed Scott Coward (Class I, term to 2028, Audit Committee) and Paul Kuznik (Class II, term to 2029, Commercial Committee) on September 22, 2026.
Coward was EVP, Chief Legal Officer and CAO of Exact Sciences from January 2015 to December 2022 and led the Genomic Health integration; he has been an attorney at K&L Gates since July 2026.
Kuznik was CEO of Bolton Medical (2015-2018) through its acquisition by Terumo, then President of Terumo Aortic North America from 2020 to 2023.
Each director receives a $50,000 annual cash retainer, $5,000 per committee, and an option for 125,000 HUMA shares under the non-employee director program.
CEO Laura Niklason cited the additions as Humacyte expands the Symvess launch and prepares the ATEV commercial launch for dialysis access.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.